BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

956 related articles for article (PubMed ID: 23374268)

  • 1. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
    Hylander T; Latif L; Petersson-Westin U; Cardell LO
    J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial.
    Hylander T; Larsson O; Petersson-Westin U; Eriksson M; Kumlien Georén S; Winqvist O; Cardell LO
    Respir Res; 2016 Jan; 17():10. PubMed ID: 26817454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
    Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
    J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
    Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
    J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals.
    TePas EC; Hoyte EG; McIntire JJ; Umetsu DT
    Ann Allergy Asthma Immunol; 2004 Jan; 92(1):25-31. PubMed ID: 14756461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis.
    Powell RJ; Frew AJ; Corrigan CJ; Durham SR
    Allergy; 2007 Nov; 62(11):1335-8. PubMed ID: 17714551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation.
    Möbs C; Slotosch C; Löffler H; Jakob T; Hertl M; Pfützner W
    J Immunol; 2010 Feb; 184(4):2194-203. PubMed ID: 20048125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
    Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
    Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 5-Year Open-Label Follow-up of a Randomized Double-Blind Placebo-Controlled Trial of Intralymphatic Immunotherapy for Birch and Grass Allergy Reveals Long-term Beneficial Effects.
    Hjalmarsson E; Hellkvist L; Karlsson A; Winquist O; Kumlien Georén S; Westin U; Cardell LO
    J Investig Allergol Clin Immunol; 2023 Oct; 33(5):362-372. PubMed ID: 37843385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluctuation of Disease Severity and Quality of Life Applying Intralymphatic Immunotherapy for Patients with Seasonal Allergic Rhinitis.
    Khoshkhui M; Jabbari F; Shafiee Zargar F; Motavalli Haghi N; Ariaee N
    Iran J Allergy Asthma Immunol; 2024 Apr; 23(2):149-157. PubMed ID: 38822510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy.
    Bonvalet M; Moussu H; Wambre E; Ricarte C; Horiot S; Rimaniol AC; Kwok WW; Horak F; de Beaumont O; Baron-Bodo V; Moingeon P
    Clin Exp Allergy; 2012 Dec; 42(12):1745-55. PubMed ID: 23181790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depigmented-polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients.
    Pfaar O; Biedermann T; Klimek L; Sager A; Robinson DS
    Allergy; 2013 Oct; 68(10):1306-13. PubMed ID: 23991896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.
    Panzner P; Petrás M; Sýkora T; Lesná I
    Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: A 3-year randomized placebo-controlled trial.
    Skaarup SH; Schmid JM; Skjold T; Graumann O; Hoffmann HJ
    J Allergy Clin Immunol; 2021 Mar; 147(3):1011-1019. PubMed ID: 32679209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intralymphatic immunotherapy with birch and grass pollen extracts. A randomized double-blind placebo-controlled clinical trial.
    Ahlbeck L; Ahlberg E; Stuivers L; Björkander J; Nyström U; Retsas P; Govindaraj D; Jenmalm MC; Duchén K
    Clin Exp Allergy; 2023 Aug; 53(8):809-820. PubMed ID: 37013723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
    Roberts G; Hurley C; Turcanu V; Lack G
    J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bet v 1-specific IgA increases during the pollen season but not after a single allergen challenge in children with birch pollen-induced intermittent allergic rhinitis.
    Keen C; Johansson S; Reinholdt J; Benson M; Wennergren G
    Pediatr Allergy Immunol; 2005 May; 16(3):209-16. PubMed ID: 15853949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.